Simons, Robert L., Antonio Davila, and Afroze A Mohammed. "Becton Dickinson--Designing the New Strategic, Operational, and Financial Planning Process." Harvard Business School Case 197-014, July 1996.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products.

Becton, Dickinson (NYSE:BDX), or BD, on Thursday said it had agreed to pay $85M to settle claims that it had failed to ...

On the evening of April 23, Becton Dickinson announced it had reached a deal to acquire Bard for $24bn in cash and shares – the latest in a series of major deals in the medical technology sector. A ...

Becton Dickinson & Co. agreed to acquire an Edwards Lifesciences unit for $4.2 billion, in one of the company’s largest of ...

Upgrade to begin using 40 years of financial statements and get so much more. Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all ...

I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Zacks Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off Embecta is exploring a potential sale after a nearly 70% drop in share price since its ...